• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Renal Cell Carcinoma

home / clinical-spotlight / rcc
Daniel J. George, MD, Duke University School of Medicine
July 7, 2023
Dr Daniel J. George Discusses the Use of Biomarkers in RCC Treatment
While there are reliable biomarkers to monitor disease progression and guide treatment decisions for tyrosine kinase inhibitors in renal cell carcinoma (RCC), there is a need for biomarkers for immunotherapies.
Daniel J. George, MD, Duke University School of Medicine
June 22, 2023
Site of Metastasis Is Significant in Renal Cell Carcinoma, Dr Daniel George Explains
Where renal cell carcinoma spreads can have a significant impact on prognosis and treatment options for patients.
Dr Rana McKay
May 30, 2023
Dr Rana McKay on First-Line Therapies for Metastatic Renal Cell Carcinoma
In this first part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, provides an overview of the treatment landscape for advanced renal cell carcinoma.
Dr Rana McKay
May 23, 2023
Dr Rana McKay on Second-Line Treatment Options for Advanced RCC
In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options for advanced renal cell carcinoma (RCC).
Dr Alan Tan
May 9, 2023
Dr Alan Tan on the Options for Patients With Advanced RCC
Survival is good for patients when renal cell carcinoma (RCC) is caught early, but options for advanced disease present challenges, explained Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush Medical College and the director of GU Medical Oncology.
Dr Alan Tan
May 2, 2023
Dr Alan Tan Provides Overview of RCC Prevalence, Presentation, Diagnosis
Many times, renal cell carcinoma (RCC) is found incidentally, as a result of something else, said Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush Medical College and the director of GU Medical Oncology.
© 2024 MJH Life Sciences
AJMC®
All rights reserved.